The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials.
 
Xinan Sheng
Speakers' Bureau - BeiGene; Junshi Pharmaceuticals; Novartis; Pfizer; RemeGen
 
Zhisong He
No Relationships to Disclose
 
Yanxia Shi
No Relationships to Disclose
 
Hong Luo
No Relationships to Disclose
 
Weiqing Han
No Relationships to Disclose
 
Xin Yao
No Relationships to Disclose
 
Benkang Shi
No Relationships to Disclose
 
Jiyan Liu
No Relationships to Disclose
 
Changlu Hu
No Relationships to Disclose
 
Ziling Liu
No Relationships to Disclose
 
Hongqian Guo
No Relationships to Disclose
 
Guohua Yu
No Relationships to Disclose
 
Zhigang Ji
No Relationships to Disclose
 
Shiying Yu
No Relationships to Disclose
 
Yi Hu
No Relationships to Disclose
 
Jianming Guo
No Relationships to Disclose
 
Jianming Ying
No Relationships to Disclose
 
Jianmin Fang
Employment - RemeGen
Stock and Other Ownership Interests - RemeGen
 
Aiping Zhou
No Relationships to Disclose
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere